Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2023-06-09 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2023-06-09 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document contains two letters addressed to stock exchanges reporting the outcome of a board meeting held on June 9, 2023. The first letter announces the approval of the audited financial results for the quarter and financial year ended March 31, 2023, and attaches the audited financial results and audit report. The second letter declares that the statutory auditors have issued an unmodified audit opinion on these financial results. The document length is 3170 characters, which is relatively short and primarily serves as an announcement of the audit report and financial results rather than the full report itself. It does not contain detailed financial statements or substantive financial data but rather informs the exchanges and public about the audit report and results availability. According to the "Menu vs Meal" rule, such announcements are classified as Regulatory Filings (RNS) because they announce the audit report and financial results but do not contain the full report or detailed financial data themselves.
2023-06-09 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing about the postponement of a Board Meeting due to delay in consolidation of books related to an amalgamation. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations but does not contain any financial data, report content, or detailed management information. It is an announcement about a scheduling change of a board meeting, not a report or detailed filing. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting scheduling and management communication.
2023-06-07 English
Annual Secretarial Compliance Report
Audit Report / Information Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the year ended 31st March 2023' and is issued pursuant to SEBI Circular CIR/CFD/CMD1/27/2019. It is a compliance report issued by a company secretary or compliance officer, examining the company's adherence to various SEBI regulations and secretarial standards for the financial year 2022-23. The document includes detailed compliance status, observations, and remarks related to secretarial standards, policies, website maintenance, director disqualifications, subsidiary details, document preservation, performance evaluation, related party transactions, and disclosure of events. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or certification letter. It is a standalone compliance report focused on secretarial and regulatory compliance for the year ended March 31, 2023. Therefore, the appropriate classification is Audit Report / Information (AR), as it is a standalone audit/compliance report related to regulatory adherence and internal controls, excluding full annual financial statements. FY 2023
2023-05-29 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification about the postponement of a board meeting originally scheduled to approve audited financial results for the year ended March 31, 2023. It references regulatory compliance under SEBI Listing Obligations but does not contain any financial data or the actual report. The document is short (1210 characters) and serves as an announcement of a change in schedule rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2023-05-27 English
Board Meeting — LASA SUPERGENERICS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2023 to inter-alia consider and approve the Audited Financial results of the Company for…
Regulatory Filings
2023-05-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.